Impaired NO release from bovine aortic endothelial cells exposed to activated platelets

Atherosclerosis

Volumn 128, Issue 1, 1997, Pages 19-26

  Watanabe, Ryoji ^a   Kishi, Yukio ^a   Sakita, Shin Ya ^a   Numano, Fujio ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Endothelium; Nitric oxide; Platelets; Prostacyclin

Indexed keywords

ACETYLSALICYLIC ACID; ARGININE; N(G) NITROARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTACYCLIN;

AORTA; ARTICLE; CATTLE; CELL AGGREGATION; CONTROLLED STUDY; ENDOTHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; VASCULAR ENDOTHELIUM;

ADENOSINE TRIPHOSPHATE; ANIMALS; AORTA; ARGININE; CATTLE; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROARGININE; PLATELET ACTIVATION; PLATELET AGGREGATION; SEROTONIN;

EID: 0031059088     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(96)05973-4     Document Type: Article

References (40)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801.
2. D'Angelo V, Villa S, Mysliwiec M, Donati MB, DeGaetano G. Defective fibrinolysis and prostacyclin-like activity in human atheromatous plaques. Thromb Haemost 1978;39:535.
3. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Decker T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet 1989;333:461.
4. Ohdama S, Takano S, Miyake S, Kubota T, Sato K, Aoki N. Plasma thrombomodulin as a marker of vascular injuries in collagen vascular diseases. Am J Clin Pathol 1994;101:109.
5. Blann AD, Maxwell SRJ, Burrows G, Miller JP. Antioxidants, von Willebrand factor and endothelial cell injury in hypercholesterolemia and vascular disease. Atherosclerosis 1995;116:191.
6. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;27:2002.
7. Warren JB, Pons F, Brady AJB. Nitric oxide biology: implications for cardiovascular therapeutics. Cardiovasc Res 1994;28:25.
8. de Belder AJ, Radomski MW. Nitric oxide in the clinical arena. J Hypertension 1994;12:617.
9. Stamler JS, Loh E, Roddy M, Currie KE, Creager MA. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994;89:2035.
10. Ware JA, Heistad DD. Platelet-endothelium interactions. N Engl J Med 1993;328:628.
11. Draijer R, Atsma DE, van der Laarse A, van Hinsbergh VWM. cGMP and nitric oxide modulate thrombin-induced endothelial permeability. Regulation via different pathways in human aortic and umbilical vein endothelial cells. Circ Res 1995;76:199.
12. Fujimoto T, Suzuki H, Tanoue K, Fukushima Y, Yamazaki H. Cerebrovascular injuries induced by activation of platelets in vivo. Stroke 1985;16:245.
13. Asada Y, Hayashi T, Sumiyoshi A. Vascular injuries induced by materials released from platelet-rich thrombus in vivo. Atherosclerosis 1988;70:1.
14. Jørgensen L, Grøthe AG, Larsen T, Kinlough-Rathbone RL, Mustard JF. Injury to cultured endothelial cells by thrombin-stimulated platelets. Lab Invest 1986;54:408.
15. Kishi Y, Numano F. In vitro study of vascular endothehal injury by activated platelets and its prevention. Atherosclerosis 1989;76:95.
16. Numano F, Kishi Y, Ashikaga T, Hata A, Makita T, Watanabe R. What effect does controlling platelets have on atherosclerosis? Ann NY Acad Sci 1994;748:383.
17. Radomski MW, Palmer RMJ, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987;92;639.
18. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;ii:1057.
19. Schwartz SM. Selection and characterization of bovine aortic endothelial cells. In Vitro 1978;14:966.
20. Aster RH, Jandl JH. Platelet sequestration in man. I. Methods. J Clin Invest 1964;43:966.
21. 3H]GTP-labeled human platelets. Thromb Res 1995;78:483.
22. Böhme E, Schultz G. Separation of cyclic nucleotides by thin layer chromatography on polyethyleneimine cellulose. Methods Enzymol 1974;38:27.
23. Bredt DS, Snyder SH. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci USA 1989;86:9030.
24. Michel T, Li GK, Busconi L. Phosphorylation and subcellular translocation of endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1993;90:6252.
25. Haslam RJ, Vanderwel M. Inhibition of platelet adenylate cyclase by 1-o-alkyl-2-o-sn-glyceryl-3-phosphorylcholine (platelet activating factor). J Biol Chem 1982;257:6879.
26. Kishi Y, Ashikaga T, Watanabe R, Numano F. Atrial natriuretic peptide reduces cyclic AMP by activating cyclic GMP-stimulated phosphodiesterase in vascular endothelial cells. J Cardiovasc Pharmacol 1994;23:351.
27. Schrör K. Prostaglandins, other eicosanoids and endothelial cells. Basic Res Cardiol 1985;80:502.
28. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of non-steroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994;90:11 693.
29. Gresele P, Zoja C, Deckmyn H, Arnout J, Vermylen J, Verstraete M. Dipyridamole inhibits platelet aggregation in whole blood. Thromb Haemost 1983;50:852.
30. Sweeney JD, Hoernig LA, Michnik A, Fitzpatrick JE. Whole blood aggregometry. Influence of sample collection and delay in study performance on test results. Am J Clin Pathol 1989;92:676.
31. Miller VM, Vanhoutte PM. Relaxations to SIN-1, nitric oxide, and sodium nitroprusside in canine arteries and veins. J Cardiovasc Pharmacol 1990;14(Suppl 11):67.
32. Vanhoutte PM, Shimokawa H. Endothelium-derived relaxing factor and coronary vasospasm. Circulation 1989;80:1.
33. 2 and serotonin are possible mediators. Circulation 1989;79:154.
34. Yao S, Ober JC, McNatt J, Benedict CR, Rosolowsky M, Anderson HV, Cui K, Maffrand J, Campbell WB, Buja LM, Willerson JT. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circ Res 1992;70:39.
35. Sherman CT, Litvack F, Grundfest W, Lee M, Hickey A, Chaux A, Kass R, Blanche C, Matloff J, Morgenstern L, Ganz W, Swan HJC, Forrester J. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986;315:13.
36. Chen LY, Mehta P, Mehta JL. Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets. Relevance of the effect of oxidized LDL on platelet function. Circulation 1996;93:1740.
37. Murata M, Ikeda Y, Araki Y, Murakami H, Sato K, Yamamoto M, Watanabe K, Ando Y, Igawa T, Maruyama I. Inhibition by endothelial cells of platelet aggregating activity of thrombin-role of thrombomodulin. Thromb Res 1988;50:647.
38. Weber A, Strobach H, Schrör K. Direct inhibition of platelet function by organic nitrates via nitric oxide formation. Eur J Pharmacol 1993;247:29.
39. Nishimura H, Rosenblum WI, Nelson GH, Boynton S. Agents that modify EDRF formation alter antiplatelet properties of brain arteriolar endothelium in vivo. Am J Physiol 1991;261:H15.
40. Tagami M, Ikeda K, Nara Y, Fujino H, Kubota A, Numano F, Yamori Y. Detailed examination of vascular lesions triggered by an inhibitor of endothelium-derived relaxing factor. Lab Invest 1995;72:174.